Literature DB >> 17804661

Comparison of plaque- and flow cytometry-based methods for measuring dengue virus neutralization.

Annette A Kraus1, William Messer, Laura B Haymore, Aravinda M de Silva.   

Abstract

As dengue vaccines enter clinical trials, there is a need for rapid and quantitative assays to measure neutralization. We have developed flow-based neutralization assays which generated results similar to those generated by the established, plaque reduction neutralization test. The flow assays are an improvement, as they use human cells and allow for high-throughput screening.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17804661      PMCID： PMC2168473          DOI： 10.1128/JCM.00827-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  18 in total

1.  An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies.

Authors:  Nicole C Martin; Jorge Pardo; Monika Simmons; Jeffrey A Tjaden; Susana Widjaja; Mary A Marovich; Wellington Sun; Kevin R Porter; Timothy H Burgess
Journal:  J Virol Methods       Date:  2006-01-18       Impact factor: 2.014

2.  Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

Authors:  A P Durbin; R A Karron; W Sun; D W Vaughn; M J Reynolds; J R Perreault; B Thumar; R Men; C J Lai; W R Elkins; R M Chanock; B R Murphy; S S Whitehead
Journal:  Am J Trop Med Hyg       Date:  2001-11       Impact factor: 2.345

Review 3.  The dengue viruses.

Authors:  E A Henchal; J R Putnak
Journal:  Clin Microbiol Rev       Date:  1990-10       Impact factor: 26.132

4.  Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants.

Authors:  S C Kliks; S Nimmanitya; A Nisalak; D S Burke
Journal:  Am J Trop Med Hyg       Date:  1988-03       Impact factor: 2.345

5.  Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons.

Authors:  M S Diamond; T G Roberts; D Edgil; B Lu; J Ernst; E Harris
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

6.  A plaque reduction test for dengue virus neutralizing antibodies.

Authors:  P K Russell; A Nisalak; P Sukhavachana; S Vivona
Journal:  J Immunol       Date:  1967-08       Impact factor: 5.422

7.  Human dendritic cells as targets of dengue virus infection.

Authors:  M Marovich; G Grouard-Vogel; M Louder; M Eller; W Sun; S J Wu; R Putvatana; G Murphy; B Tassaneetrithep; T Burgess; D Birx; C Hayes; S Schlesinger-Frankel; J Mascola
Journal:  J Investig Dermatol Symp Proc       Date:  2001-12

8.  Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine.

Authors:  Bruno Guy; Pornthep Chanthavanich; Sophie Gimenez; Chukiat Sirivichayakul; Arunee Sabchareon; Sarah Begue; Sutee Yoksan; Christine Luxemburger; Jean Lang
Journal:  Vaccine       Date:  2004-09-09       Impact factor: 3.641

9.  Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses.

Authors:  Erika Navarro-Sanchez; Ralf Altmeyer; Ali Amara; Olivier Schwartz; Franck Fieschi; Jean-Louis Virelizier; Fernando Arenzana-Seisdedos; Philippe Desprès
Journal:  EMBO Rep       Date:  2003-07       Impact factor: 8.807

10.  Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection.

Authors:  S B Halstead; E J O'Rourke; A C Allison
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307
View more
  95 in total

1.  Comparison of plaque- and enzyme-linked immunospot-based assays to measure the neutralizing activities of monoclonal antibodies specific to domain III of dengue virus envelope protein.

Authors:  Lidong Liu; Kun Wen; Jie Li; Dongmei Hu; Yanfen Huang; Liwen Qiu; Jianpiao Cai; Xiaoyan Che
Journal:  Clin Vaccine Immunol       Date:  2011-11-23

2.  Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells.

Authors:  Simona Zompi; Brian H Santich; P Robert Beatty; Eva Harris
Journal:  J Immunol       Date:  2011-11-30       Impact factor: 5.422

3.  Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.

Authors:  Wahala M P B Wahala; Claire Huang; Siritorn Butrapet; Laura J White; Aravinda M de Silva
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

4.  Dengue-specific CD8+ T cell subsets display specialized transcriptomic and TCR profiles.

Authors:  Yuan Tian; Mariana Babor; Jerome Lane; Grégory Seumois; Shu Liang; N D Suraj Goonawardhana; Aruna D De Silva; Elizabeth J Phillips; Simon A Mallal; Ricardo da Silva Antunes; Alba Grifoni; Pandurangan Vijayanand; Daniela Weiskopf; Bjoern Peters; Alessandro Sette
Journal:  J Clin Invest       Date:  2019-03-18       Impact factor: 14.808

5.  An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.

Authors:  Laura J White; Carlos A Sariol; Melissa D Mattocks; Wahala Wahala M P B; Vorraphun Yingsiwaphat; Martha L Collier; Jill Whitley; Rochelle Mikkelsen; Idia V Rodriguez; Melween I Martinez; Aravinda de Silva; Robert E Johnston
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

6.  Defeating dengue: a challenge for a vaccine.

Authors: 
Journal:  Nat Med       Date:  2012-11       Impact factor: 53.440

7.  Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics.

Authors:  Scott A Smith; Ruklanthi de Alwis; Nurgun Kose; Anna P Durbin; Stephen S Whitehead; Aravinda M de Silva; James E Crowe
Journal:  J Infect Dis       Date:  2013-03-22       Impact factor: 5.226

8.  Natural strain variation and antibody neutralization of dengue serotype 3 viruses.

Authors:  Wahala M P B Wahala; Eric F Donaldson; Ruklanthi de Alwis; Mary Ann Accavitti-Loper; Ralph S Baric; Aravinda M de Silva
Journal:  PLoS Pathog       Date:  2010-03-19       Impact factor: 6.823

9.  Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.

Authors:  Scott J Balsitis; Katherine L Williams; Ruben Lachica; Diana Flores; Jennifer L Kyle; Erin Mehlhop; Syd Johnson; Michael S Diamond; P Robert Beatty; Eva Harris
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

10.  HLA-DRB1 Alleles Are Associated With Different Magnitudes of Dengue Virus-Specific CD4+ T-Cell Responses.

Authors:  Daniela Weiskopf; Michael A Angelo; Alba Grifoni; Patrick H O'Rourke; John Sidney; Sinu Paul; Aruna D De Silva; Elizabeth Phillips; Simon Mallal; Sunil Premawansa; Gayani Premawansa; Ananda Wijewickrama; Bjoern Peters; Alessandro Sette
Journal:  J Infect Dis       Date:  2016-07-20       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.